Display options
Share it on

Kidney Int. 2015 Dec;88(6):1217-1218. doi: 10.1038/ki.2015.328.

Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseases.

Kidney international

Sanjeev Noel, Abdel R A Hamad, Hamid Rabb

Affiliations

  1. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  2. Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.

PMID: 26649656 PMCID: PMC5267352 DOI: 10.1038/ki.2015.328

Abstract

The transcription factor Nrf2 plays an important role in many kidney diseases from acute kidney injury to chronic kidney disease, and there have been preliminary Nrf2-based therapeutic trials in humans. Shelton et al. presents an integrated transcriptomic and proteomic analysis of mouse kidney to reveal Nrf2 targets with potentially important roles in kidney homeostasis and pathophysiology. These results can further our understanding of Nrf2-based mechanisms and help in the development of therapeutics for a wide range of kidney diseases.

References

  1. FASEB J. 2006 Dec;20(14):2624-6 - PubMed
  2. J Nephrol. 2015 Aug;28(4):495-501 - PubMed
  3. N Engl J Med. 2011 Jul 28;365(4):327-36 - PubMed
  4. J Am Soc Nephrol. 2015 Dec;26(12 ):2989-3000 - PubMed
  5. Am J Physiol Renal Physiol. 2011 May;300(5):F1180-92 - PubMed
  6. Kidney Int. 2009 Aug;76(3):277-85 - PubMed
  7. Am J Nephrol. 2014;39(6):499-508 - PubMed
  8. Cancer Cell. 2011 Oct 18;20(4):418-20 - PubMed
  9. Kidney Int. 2015 Dec;88(6):1261-1273 - PubMed
  10. Kidney Int. 2014 Jan;85(1):134-41 - PubMed

Publication Types

Grant support